Update on Post-Recurrence Survival After Pancreatic Cancer Resection: A Comprehensive Systematic Review
Clicks: 4
ID: 315715
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.9
/100
4 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #129 of 432 articles by views in the british journal of surgery
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background The burden of recurrence after resection of pancreatic-ductal-adenocarcinoma (PDAC) remains very high, leading to a dismal prognosis. Post-recurrence survival (PRS) and its determinants have been less studied compared to traditional outcomes like overall and recurrence-free survival. Aims To provide an update on PRS after PDAC resection and identify its prognostic determinants. Methods A PRISMA-compliant systematic literature review was performed, searching studies published in the period January 01/2010-12/2025 (PubMed/Scopus/Web of Science). The population, intervention, comparator, outcome (PICO) strategy was used to formulate study questions and select studies: Population/Intervention) original studies including patients who had resection of non-metastatic PDAC and specifically reporting PRS; Comparator) timing/pattern/treatment of recurrence; Outcomes) PRS defined as survival after PDAC recurrence, site- and treatment-specific PRS, predictors of PRS. Results Forty-five eligible studies were identified. Median PRS range was 2.6-44.0 months. Local recurrence (remnant pancreas or locoregional lymph nodes) and lung-limited recurrence had longer PRS (range, 5.0-20.0 months and 8.5-32.5 months respectively) compared to liver recurrence (range, 5.1-8.5 months). Peritoneal or multisite recurrence had the shortest PRS. Whenever oncologically/technically feasible, completion pancreatectomy (i.e., isolated local recurrence), and resection of limited recurrence in the lungs or regional/retroperitoneal lymph nodes were associated with longer PRS, compared to systemic treatment alone. Combined local and systemic treatment had a positive effect on PRS, compared to systemic chemotherapy alone. Prolonged PRS was associated with asymptomatic recurrence or low performance status, routine/active follow-up, longer recurrence-free survival after first pancreatectomy, lung-only/isolated local recurrence, resectable recurrence, young age, serum albumin and Ca19-9 levels at recurrence, adjuvant chemotherapy after index pancreatectomy. Conclusion PRS varies widely based on pattern/timing/treatment of recurrences. Systemic control of the disease is pivotal. Patients eligible for radical treatments (i.e., completion pancreatectomy) or showing favorable tumor biology (isolated lung recurrence), may achieve very long PRS. The impact of neoadjuvant therapy (before index pancreatectomy) on PRS is still unexplored.
| Reference Key |
openalex_W7163401389
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | L Bernardi, E Garosi, R Roesel, M Cefalì, G Pesola, L Deantonio, P Majno-Hurst, S de Dosso, A Cristaudi |
| Journal | the british journal of surgery |
| Year | 2026 |
| DOI |
10.1093/bjs/znag055.039
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.